Iwasaki Hitoshi, Yagyu Hiroaki, Shimano Hitoshi
Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba.
Department of Endocrinology and Metabolism, Tsukuba University Hospital Mito Clinical Education and Training Center, Mito Kyodo General Hospital.
J Atheroscler Thromb. 2025 May 1;32(5):550-559. doi: 10.5551/jat.65551. Epub 2025 Jan 10.
Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), is a pervasive chronic disease that affects millions of people worldwide. It predisposes individuals to a range of severe microvascular and macrovascular complications, which drastically impact the patient's quality of life and increase mortality rates owing to various comorbidities. This extensive review explores the intricate pathophysiology underlying diabetic complications, focusing on key mechanisms, such as atherosclerosis, insulin resistance, chronic inflammation, and endothelial dysfunction. It also highlights recent therapeutic advancements, including the introduction of SGLT2 inhibitors and GLP-1 receptor agonists, which provide benefits beyond glycemic control and offer cardiovascular and renal protection. Furthermore, the future position of SGLT2 inhibitors and GLP-1 receptor agonists in terms of the prevention of diabetes and macrovascular diseases will be discussed. Considering the differences in insulin secretion capacity between Western and Asian patients, including Japanese patients, we propose a treatment strategy for high-quality diabetes in Japan.
糖尿病,尤其是2型糖尿病(T2DM),是一种普遍存在的慢性疾病,影响着全球数百万人。它使个体易患一系列严重的微血管和大血管并发症,这些并发症极大地影响患者的生活质量,并由于各种合并症而增加死亡率。这篇全面的综述探讨了糖尿病并发症背后复杂的病理生理学,重点关注关键机制,如动脉粥样硬化、胰岛素抵抗、慢性炎症和内皮功能障碍。它还强调了最近的治疗进展,包括引入钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和胰高血糖素样肽-1(GLP-1)受体激动剂,这些药物除了控制血糖外还具有益处,并提供心血管和肾脏保护。此外,还将讨论SGLT2抑制剂和GLP-1受体激动剂在预防糖尿病和大血管疾病方面的未来地位。考虑到西方患者与亚洲患者(包括日本患者)在胰岛素分泌能力上的差异,我们提出了日本高质量糖尿病的治疗策略。